Abstract
Insomnia is common among elderly people and nearly 30 to 40% of the adult population also suffer from insomnia. Pharmacological treatment of insomnia include the use of benzodiazepine and non-benzodiazepine drugs like zolpidem, zaleplon,Zopiclone. Although these drugs improve sleep ,their usage is also associated with number of adverse effects, Melatonin ,the hormone secreted by the pineal gland of all animals and human beings has been used for treatment of insomnias,since the timing of its secretion in humans as well as in most of the animals coincides with the increase of nocturnal sleep propensity.Because of its short half life,melatonin slow release preparations were introduced for treatment of insomnia. Recently ramelteon ,a selective MT1,MT2 receptor agonist with greater efficacy of action in treating insomnia has been used clinically and has been found effective in improving sleep quality ,sleep efficacy and also in reducing the sleep onset time when compared to melatonin or slow melatonin preparations.The mechanism of action of ramelteon in improving sleep is discussed in the paper. Another melatonergic drug agomelatine besides acting on MT1/MT2 receptors also displays 5-HT2c antagonism and this drug has been found effective as a novel antidepressant for treating major depressive disorders.Agomelatine besides causing remission of depressive symptoms also improves sleep quality and efficiency. Other antidepressants depressants that are in clinical use today do not improve sleep. There are other melatonergic drugs like tasimelteon ,6-chloromelatonin.But ramelteon and agomelatine deserve special attention for treatment of insomnia and sleep disturbances associated with depressive disorders and have promising role for treatment of sleep disorders.
Keywords: Ramelteon, Sleep, Agomelatine, Depression, Insomnia, Melatonin, Suprachiasmatic Nucleus, sleep-wake cycle, Homeostatic Process, Hypothalamus
CNS & Neurological Disorders - Drug Targets
Title:Melatonergic Drugs for Therapeutic Use in Insomnia and Sleep Disturbances of Mood Disorders
Volume: 11 Issue: 2
Author(s): Venkatramanujam Srinivasan, Rahimah Zakaria, Zahiruddin Othaman, Amnon Brzezinski, Atul Prasad, Gregory M. Brown
Affiliation:
Keywords: Ramelteon, Sleep, Agomelatine, Depression, Insomnia, Melatonin, Suprachiasmatic Nucleus, sleep-wake cycle, Homeostatic Process, Hypothalamus
Abstract: Insomnia is common among elderly people and nearly 30 to 40% of the adult population also suffer from insomnia. Pharmacological treatment of insomnia include the use of benzodiazepine and non-benzodiazepine drugs like zolpidem, zaleplon,Zopiclone. Although these drugs improve sleep ,their usage is also associated with number of adverse effects, Melatonin ,the hormone secreted by the pineal gland of all animals and human beings has been used for treatment of insomnias,since the timing of its secretion in humans as well as in most of the animals coincides with the increase of nocturnal sleep propensity.Because of its short half life,melatonin slow release preparations were introduced for treatment of insomnia. Recently ramelteon ,a selective MT1,MT2 receptor agonist with greater efficacy of action in treating insomnia has been used clinically and has been found effective in improving sleep quality ,sleep efficacy and also in reducing the sleep onset time when compared to melatonin or slow melatonin preparations.The mechanism of action of ramelteon in improving sleep is discussed in the paper. Another melatonergic drug agomelatine besides acting on MT1/MT2 receptors also displays 5-HT2c antagonism and this drug has been found effective as a novel antidepressant for treating major depressive disorders.Agomelatine besides causing remission of depressive symptoms also improves sleep quality and efficiency. Other antidepressants depressants that are in clinical use today do not improve sleep. There are other melatonergic drugs like tasimelteon ,6-chloromelatonin.But ramelteon and agomelatine deserve special attention for treatment of insomnia and sleep disturbances associated with depressive disorders and have promising role for treatment of sleep disorders.
Export Options
About this article
Cite this article as:
Venkatramanujam Srinivasan, Rahimah Zakaria, Zahiruddin Othaman, Amnon Brzezinski, Atul Prasad, Gregory M. Brown , Melatonergic Drugs for Therapeutic Use in Insomnia and Sleep Disturbances of Mood Disorders, CNS & Neurological Disorders - Drug Targets 2012; 11 (2) . https://dx.doi.org/10.2174/187152712800269740
DOI https://dx.doi.org/10.2174/187152712800269740 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Thematic Issue: Towards New Approaches in Alzheimer’s Research and Alzheimer’s Disease)
Current Alzheimer Research Cannabinoids and Cardiovascular Disease: The Outlook for Clinical Treatments
Current Vascular Pharmacology Synthesis of Novel 2-(Methylthio)benzo[g][1,2,4]triazolo[1,5-a]quinazolin- 5-(4H)-one and its Derivatives
Letters in Organic Chemistry Cytogenomic Bioinformatics: Practical Issues
Current Bioinformatics Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection
Current Pharmaceutical Design A Comprehensive Review on the Biological and Pharmacological Activities of Rhodanine Based Compounds for Research and Development of Drugs
Mini-Reviews in Medicinal Chemistry Inflammation and Age-Related Iron Accumulation in F344 Rats
Current Aging Science The Interaction Between Burn Injury and Vitamin D Metabolism and Consequences for the Patient
Current Clinical Pharmacology Amantadine, Apomorphine and Zolpidem in the Treatment of Disorders of Consciousness
Current Pharmaceutical Design Advancement of Technology for Drug Discovery and Development – Part II
Current Topics in Medicinal Chemistry Topical Anesthetics for Procedural Pain in Children: What Does the Future Hold?
Current Drug Therapy New Route to Synthesize Fluorine Substituted Lamotrigine Drug Analogues as an Anti-Inflammatory Agent
Current Organic Synthesis An Appraisal of Current Pharmacological Perspectives of Sesamol: A Review
Mini-Reviews in Medicinal Chemistry Expression and Function of the Leukocyte Integrins in Medicine
Current Genomics Cytotoxic T Lymphocyte Antigen 4 Gene +49 A/G (rs231775) Polymorphism and Susceptibility to Systemic Lupus Erythematosus
Current Rheumatology Reviews Neurochemistry and Pharmacological Treatments: Where is the Field of Anorexia Nervosa Heading?
Central Nervous System Agents in Medicinal Chemistry Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers
Current Topics in Medicinal Chemistry Thromboxane A<sub>2</sub> Receptor Polymorphism in Association with Cerebral Infarction and its Regulation on Platelet Function
Current Neurovascular Research The Role of the ATP-Binding Cassette Transporter P-Glycoprotein in the Transport of β-Amyloid Across the Blood-Brain Barrier
Current Pharmaceutical Design NAP, A Neuroprotective Drug Candidate in Clinical Trials, Stimulates Microtubule Assembly in the Living Cell
Current Alzheimer Research